ALK and non-small cell lung carcinoma: To explore whether acquired resistance to first-generation crizotinib might be accompanied by cross-resistance to second- and third-generation ALK–TKIs in an EMT-dependent manner, we characterized two crizotinib-resistant sublines (H2228/CR and H3122/CR) derived from the crizotinib-sensitive H2228 and H3122 NSCLC cell lines harboring the ALK variants 3a/b and 1, respectively [56].